Sartorius Stedim Biotech : Q3 due 20 October – Another strong quarter ahead
>Q3 will not show a meaningful deterioration - Even though the basis in H2 is now higher in 2020, we estimate sales to have increased by 49% y-o-y (+52% y-o-y excl. forex) to € 759m. A continuously increasing demand from coronavirus vaccine manufacturers, strong demand for products to develop new coronavirus therapies (pandemic-related effects boosted sales by +26% y-o-y in H1 2021), M&A, stocking, and importantly, also a strong “core” demand (c. +20% y-o-y estimated ...Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.